Effects of Positive Expiratory Pressure on Gas Exchange, Atelectasis, Hemodynamics, and Dyspnea in Spontaneously Breathing Critically Ill Subjects.

Background: The EzPAP Positive Airway Pressure System (EzPAP) is a noninvasive positive expiratory pressure (PEP) device designed to promote lung expansion. The aim of this study was to evaluate the effects of PEP on gas exchange. Secondary objectives included assessing the early effects of PEP on r...

Descripción completa

Detalles Bibliográficos
Publicado en:Respiratory Care Vol. 70; no. 3; pp. 233 - 244
Autores principales: Masuello, Denise, Servetti, Adriano, Caiffa, Salvatore, Cara, Robertina, Pieri, Chiara, Arriagada, Ricardo, Al-Husinat, Lou'i, Ball, Lorenzo, Robba, Chiara, Brunetti, Iole, Patroniti, Nicolò, Silva, Pedro Leme, Rocco, Patricia RM, Battaglini, Denise
Formato: CEU clinical trial research tables/charts Journal Article
Publicado: Mary Ann Liebert, Inc. Mar2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=183410943&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 183410943
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00201324
        4GG
      jtl: Respiratory Care
      issn: 00201324
      maglogo: N
    pubinfo:
      dt: Mar2025
      vid: 70
      iid: 3
      pid: 1365
      pub: Mary Ann Liebert, Inc.
      place: New Rochelle, New York
    artinfo:
      ui:
        183410943
        183410943
        183410943
        10.4187/respcare.12000
        183410943
      ppf: 233
      ppct: 11
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Effects of Positive Expiratory Pressure on Gas Exchange, Atelectasis, Hemodynamics, and Dyspnea in Spontaneously Breathing Critically Ill Subjects.
      aug:
        au:
          Masuello, Denise
          Servetti, Adriano
          Caiffa, Salvatore
          Cara, Robertina
          Pieri, Chiara
          Arriagada, Ricardo
          Al-Husinat, Lou'i
          Ball, Lorenzo
          Robba, Chiara
          Brunetti, Iole
          Patroniti, Nicolò
          Silva, Pedro Leme
          Rocco, Patricia RM
          Battaglini, Denise
        affil: Ms. Masuello is affiliated with Hospital General de Agudos D. F. Santojanni, Buenos Aires, Argentina
      sug:
        subj:
          Positive End-Expiratory Pressure
          Pulmonary Gas Exchange
          Pulmonary Atelectasis Therapy
          Hemodynamics
          Dyspnea Therapy
          Tracheostomy
          Critically Ill Patients
          Treatment Outcomes
          Patient Safety
          Education, Continuing (Credit)
          Italy
          Human
          Academic Medical Centers
          Clinical Trials
          Pretest-Posttest Design
          Scales
          Middle Age
          Aged
          Male
          Female
          Intensive Care Units
          T-Tests
          Mann-Whitney U Test
          Chi Square Test
          Spearman's Rank Correlation Coefficient
          Data Analysis Software
          Descriptive Statistics
          Length of Stay
          Protocols
          Respiratory Tract Physiology
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Background: The EzPAP Positive Airway Pressure System (EzPAP) is a noninvasive positive expiratory pressure (PEP) device designed to promote lung expansion. The aim of this study was to evaluate the effects of PEP on gas exchange. Secondary objectives included assessing the early effects of PEP on radiological atelectasis score (RAS), hemodynamics, and dyspnea. These outcomes were compared between spontaneously breathing subjects with and without tracheostomy. Methods: This observational single-center study was conducted at a university hospital. Inclusion criteria were spontaneously breathing adult subjects with RAS ≥ 2 and a worsened PaO2/FIO2. Exclusion criteria included life-threatening conditions, intracranial hypertension, hemodynamic instability, and pneumothorax. Gas-exchange, hemodynamic parameters, and dyspnea measured with the Respiratory Distress Observation Scale (RDOS) were assessed at 3 time points: T0 (before PEP), T1 (immediately after PEP), and T2 (2 h after PEP). RAS was assessed at T0 and 1-week post treatment (T3). Results: Of 213 patients assessed for eligibility, 186 were excluded for various reasons, leaving 27 subjects (19 without and 8 with tracheostomy) enrolled in the study. The median [interquartile range] age was 65 [58–74] y, with 66.7% being male. In the overall sample and in subjects without tracheostomy, PaO2/FIO2 did not differ significantly between T1 and T0 (P =.52 and P =.54, respectively) or between T2 and T0 (P =.47 and P =.85, respectively). In subjects with tracheostomy, PaO2/FIO2was higher at T1 compared to T0 (P =.039) but not between T2 and T0 (P =.58). Arterial PaO2 and hemodynamic parameters remained unchanged in the overall cohort. The RAS improved within 1 week of treatment in the overall cohort (T3 vs T0, P < .001) and in subjects without tracheostomy (T3 vs T0, P =.001). However, PEP therapy did not improve RDOS. Conclusions: In critically ill, spontaneously breathing subjects, PEP therapy significantly improved RAS without affecting hemodynamic stability or respiratory symptoms.
      pubtype: Academic Journal
      doctype:
        CEU
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N